EichorEICHOR
Condition: Uterine Fibroids And Heavy Menstrual Bleeding Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Uterine Fibroids And Heavy Menstrual Bleeding

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms
Phase N/A · 3 location(s) · Swiss GO Trial Group · NCT07397715Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia
Phase 2 · 1 location(s) · Shenzhen Kangzhe Biotechnology Co., Ltd. · NCT07402369Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06671548to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia
Phase 3 · 1 location(s) · JW Pharmaceutical · NCT07378098A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uteri
Phase 3 · 120 location(s) · Sumitomo Pharma Switzerland GmbH · NCT05862272HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids
NA · 1 location(s) · Chinese University of Hong Kong · NCT06692335
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.